Ticagrelor
Product Specifications
CAS Number
274693-27-5
Target
Cytochromes P450, P2Y Receptor
Related Pathways
Metabolism, Neuroscience, GPCR/G Protein
Purity
>99.99%
Bioactivity
Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique (EU) and Possia (EU) .
Smiles
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Molecular Formula
C23H28F2N6O4S
Molecular Weight
522.57
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15158882 1 Vial
Lentiviral human PSMB4 shRNA (UAS) - Lentiviral human PSMB4 shRNA (UAS, iRFP) (25)
Sign In for Pricing
View Details 
27638116 3x 1.0 µg
Lrrc3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)
Sign In for Pricing
View Details 
246510-ML550 100 µL
GBX2 (Gastrulation Brain Homeobox 2) (MaxLight 550)
Sign In for Pricing
View Details